Ovarian cancer is the second most common cause of gynecologic cancer death in women
around the world. The outcomes are complicated, because the disease is often diagnosed …

Epithelial ovarian cancer generally presents at an advanced stage and is the most common
cause of gynaecological cancer death. Treatment requires expert multidisciplinary care …

Background Olaparib has shown significant clinical benefit as maintenance therapy in
women with newly diagnosed advanced ovarian cancer with a BRCA mutation. The effect of …

Background In the PAOLA-1/ENGOT-ov25 primary analysis, maintenance olaparib plus
bevacizumab demonstrated a significant progression-free survival (PFS) benefit in newly …

Background In recurrent ovarian cancer, poly (ADP-ribose) polymerase (PARP)-inhibiting
agents have transformed the treatment of platinum-sensitive disease. New data support use …

In ovarian cancer patients, tumor fibrosis and angiotensin-driven fibrogenic signaling have
been shown to inversely correlate with survival. We sought to enhance drug delivery and …

ABCB1 encodes Multidrug Resistance protein (MDR1), an ATP-binding cassette member
involved in the cellular efflux of chemotherapeutic drugs. Here we report that ovarian and …

Ovarian cancer is the most lethal gynecologic malignancy. Platinum-based chemotherapy is
the backbone of treatment for ovarian cancer, and although the majority of patients initially …

The high mortality rate of ovarian cancer is connected with the development of acquired
resistance to multiple cancer drugs, especially cisplatin. Activation of cytoprotective …

Opinion statement Poly-ADP-ribose polymerase inhibitors (PARPi) are a class of anti-cancer
drugs that target DNA repair pathways and have shown promising efficacy in patients with …